Our pipeline is rich with opportunity

OncoResponse's antibodies to key targets reverse and relieve immunosuppression in the tumor microenvironment in the effort to enhance responses from immunotherapy for greater cures. See our platform for our ongoing discovery of rare human antibodies derived from Elite Responders.

timeline of company antibodies in various stages of preclinical and clinical development advancement

Our lead drug OR2805 is advancing through clinical studies across multiple tumor types. OR2805 reprograms M2-like TAMs leading to increased adaptive T-cell activation and proliferation. Additional antibodies are in development that modulate immune cell activity.

                        graph indicating OR2805 superior anti-PD-1